BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30:387-394. [PMID: 20839030 DOI: 10.1007/s10637-010-9532-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Vandewynckel YP, Coucke C, Laukens D, Devisscher L, Paridaens A, Bogaerts E, Vandierendonck A, Raevens S, Verhelst X, Van Steenkiste C, Libbrecht L, Geerts A, Van Vlierberghe H. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma. Oncotarget 2016;7:34988-5000. [PMID: 27167000 DOI: 10.18632/oncotarget.9222] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
2 Örd T, Örd D, Kaikkonen MU, Örd T. Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib. Cancers (Basel) 2021;13:2341. [PMID: 34066165 DOI: 10.3390/cancers13102341] [Reference Citation Analysis]
3 Baiz D, Dapas B, Farra R, Scaggiante B, Pozzato G, Zanconati F, Fiotti N, Consoloni L, Chiaretti S, Grassi G. Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines. World J Gastroenterol 2014; 20(3): 795-803 [PMID: 24574752 DOI: 10.3748/wjg.v20.i3.795] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
4 Wu MY, Yiang GT, Cheng PW, Chu PY, Li CJ. Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. J Clin Med. 2018;7. [PMID: 30104473 DOI: 10.3390/jcm7080213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
5 Yang Z, Liu S, Zhu M, Zhang H, Wang J, Xu Q, Lin K, Zhou X, Tao M, Li C. PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway. Sci Rep. 2016;6:22090. [PMID: 26915315 DOI: 10.1038/srep22090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
6 Augello G, Modica M, Azzolina A, Puleio R, Cassata G, Emma MR, Di Sano C, Cusimano A, Montalto G, Cervello M. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells. Cell Death Dis 2018;9:28. [PMID: 29348495 DOI: 10.1038/s41419-017-0195-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
7 Li J, Xiong X, Wang Z, Zhao Y, Shi Z, Zhao M, Ren T. In vitro high-throughput drug sensitivity screening with patient-derived primary cells as a guide for clinical practice in hepatocellular carcinoma-A retrospective evaluation. Clin Res Hepatol Gastroenterol 2020;44:699-710. [PMID: 32014387 DOI: 10.1016/j.clinre.2020.01.003] [Reference Citation Analysis]
8 Wang LN, Wang Y, Lu Y, Yin ZF, Zhang YH, Aslanidi GV, Srivastava A, Ling CQ, Ling C. Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. J Integr Med 2014;12:20-34. [PMID: 24461592 DOI: 10.1016/S2095-4964(14)60003-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
9 Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 2013;57:1068-77. [PMID: 23112096 DOI: 10.1002/hep.26120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
10 Kaplan GS, Torcun CC, Grune T, Ozer NK, Karademir B. Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect. Free Radical Biology and Medicine 2017;103:1-13. [DOI: 10.1016/j.freeradbiomed.2016.12.007] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
11 Toffanin S, Cornella H, Harrington A, Llovet JM. HCC Is promoted by bacterial translocation and TLR-4 signaling: a new paradigm for chemoprevention and management. Hepatology 2012;56:1998-2000. [PMID: 23115011 DOI: 10.1002/hep.26080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
12 Grande E, Earl J, Fuentes R, Carrato A. New targeted approaches against the ubiquitin–proteasome system in gastrointestinal malignancies. Expert Review of Anticancer Therapy 2014;12:457-67. [DOI: 10.1586/era.12.26] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Liu GM, Zhang YM. Targeting FBPase is an emerging novel approach for cancer therapy. Cancer Cell Int 2018;18:36. [PMID: 29556139 DOI: 10.1186/s12935-018-0533-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
14 Huang Z, Wu Y, Zhou X, Xu J, Zhu W, Shu Y, Liu P. Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol 2014;10:1795-807. [PMID: 25303058 DOI: 10.2217/fon.14.30] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
15 Huntington JT, Tang X, Kent LN, Schmidt CR, Leone G. The Spectrum of E2F in Liver Disease--Mediated Regulation in Biology and Cancer. J Cell Physiol 2016;231:1438-49. [PMID: 26566968 DOI: 10.1002/jcp.25242] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
16 Xia SW, Wang ZM, Sun SM, Su Y, Li ZH, Shao JJ, Tan SZ, Chen AP, Wang SJ, Zhang ZL, Zhang F, Zheng SZ. Endoplasmic reticulum stress and protein degradation in chronic liver disease. Pharmacol Res 2020;161:105218. [PMID: 33007418 DOI: 10.1016/j.phrs.2020.105218] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
17 Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. BMC Cancer. 2012;12:166. [PMID: 22559167 DOI: 10.1186/1471-2407-12-166] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
18 Quartu M, Carozzi VA, Dorsey SG, Serra MP, Poddighe L, Picci C, Boi M, Melis T, Del Fiacco M, Meregalli C, Chiorazzi A, Renn CL, Cavaletti G, Marmiroli P. Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve. Biomed Res Int 2014;2014:180428. [PMID: 24877063 DOI: 10.1155/2014/180428] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
19 Farra R, Dapas B, Baiz D, Tonon F, Chiaretti S, Del Sal G, Rustighi A, Elvassore N, Pozzato G, Grassi M. Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells. Biochimie. 2015;112:85-95. [PMID: 25742740 DOI: 10.1016/j.biochi.2015.02.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
20 Saeki I, Terai S, Fujisawa K, Takami T, Yamamoto N, Matsumoto T, Hirose Y, Murata Y, Yamasaki T, Sakaida I. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. J Gastroenterol. 2013;48:738-750. [PMID: 23011081 DOI: 10.1007/s00535-012-0675-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
21 Malz M, Aulmann A, Samarin J, Bissinger M, Longerich T, Schmitt S, Schirmacher P, Breuhahn K. Nuclear accumulation of seven in absentia homologue-2 supports motility and proliferation of liver cancer cells. Int J Cancer 2012;131:2016-26. [PMID: 22323152 DOI: 10.1002/ijc.27473] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
22 Montella L, Palmieri G, Addeo R, Del Prete S. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? World J Gastroenterol 2016; 22(27): 6114-6126 [PMID: 27468204 DOI: 10.3748/wjg.v22.i27.6114] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
23 Liang YC, Wang JL, Wang HT, Liu H, Zhang HL, Liang YX. ADRM1 as a therapeutic target in hepatocellular carcinoma. Kaohsiung J Med Sci 2021;37:47-54. [PMID: 32916039 DOI: 10.1002/kjm2.12298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Yang Y, Vankayalapati H, Tang M, Zheng Y, Li Y, Ma C, Lai K. Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents. Molecules 2020;25:E645. [PMID: 32028604 DOI: 10.3390/molecules25030645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2013;2:345-64. [PMID: 24400222 DOI: 10.1159/000343850] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
26 Sun J, Wang B, Liu Y, Zhang L, Ma A, Yang Z, Ji Y, Liu Y. Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression. Cancer Lett 2014;355:25-33. [PMID: 25242357 DOI: 10.1016/j.canlet.2014.09.022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
27 Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L. Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol 2015;2:e974463. [PMID: 27308423 DOI: 10.4161/23723556.2014.974463] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
28 Chen YJ, Wu H, Shen XZ. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy. Cancer Lett 2016;379:245-52. [PMID: 26193663 DOI: 10.1016/j.canlet.2015.06.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
29 Jin X, Pan Y, Wang L, Zhang L, Ravichandran R, Potts PR, Jiang J, Wu H, Huang H. MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. Oncogenesis 2017;6:e312. [PMID: 28394358 DOI: 10.1038/oncsis.2017.21] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
30 Cheng CW, Leong KW, Tse E. Understanding the role of PIN1 in hepatocellular carcinoma. World J Gastroenterol 2016; 22(45): 9921-9932 [PMID: 28018099 DOI: 10.3748/wjg.v22.i45.9921] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
31 Huang IT, Dhungel B, Shrestha R, Bridle KR, Crawford DHG, Jayachandran A, Steel JC. Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma. Expert Opin Investig Drugs 2019;28:7-18. [PMID: 30474444 DOI: 10.1080/13543784.2019.1551359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
32 Yin J, Zhu JM, Shen XZ. The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma. Int J Cancer. 2015;136:249-257. [PMID: 24420637 DOI: 10.1002/ijc.28717] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
33 Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol. 2015;50:261-272. [PMID: 25270965 DOI: 10.1007/s00535-014-1000-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
34 Wu YX, Yang JH, Saitsu H. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance. Oncotarget 2016;7:77622-34. [PMID: 27769058 DOI: 10.18632/oncotarget.12731] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
35 Dai Q, Zhang C, Yuan Z, Sun Q, Jiang Y. Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opinion on Drug Discovery 2020;15:243-58. [DOI: 10.1080/17460441.2020.1696769] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
36 Chang AY, Wang M. In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. Anticancer Drugs. 2013;24:251-259. [PMID: 23187461 DOI: 10.1097/cad.0b013e32835ba289] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
37 Johnson DE. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer. 2015;22:T1-17. [PMID: 24659480 DOI: 10.1530/erc-14-0005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
38 Suares A, Mori Sequeiros Garcia M, Paz C, González-pardo V. Antiproliferative effects of Bortezomib in endothelial cells transformed by viral G protein-coupled receptor associated to Kaposi's sarcoma. Cellular Signalling 2017;32:124-32. [DOI: 10.1016/j.cellsig.2017.01.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
39 Obara A, Fujita Y, Abudukadier A, Fukushima T, Oguri Y, Ogura M, Harashima S, Hosokawa M, Inagaki N. DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells. Biochem Biophys Res Commun 2015;460:1047-52. [PMID: 25843797 DOI: 10.1016/j.bbrc.2015.03.148] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
40 Wu TJ, Chang SS, Li CW, Hsu YH, Chen TC, Lee WC, Yeh CT, Hung MC. Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial-Mesenchymal Transition after Resection. Clin Cancer Res 2016;22:1800-12. [PMID: 26655845 DOI: 10.1158/1078-0432.CCR-15-0780] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
41 Soong RS, Anchoori RK, Roden RBS, Cho RL, Chen YC, Tseng SC, Huang YL, Liao PC, Shyu YC. Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling. BMC Cancer 2020;20:386. [PMID: 32375699 DOI: 10.1186/s12885-020-06896-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Honma Y, Shimizu S, Takehara T, Harada M. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases. J Gastroenterol 2014;49:517-26. [DOI: 10.1007/s00535-013-0796-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
43 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
44 Ciombor KK, Feng Y, Benson AB, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 2014;32:1017-1027. [PMID: 24890858 DOI: 10.1007/s10637-014-0111-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]